Shares of PRA Health Sciences Inc (NASDAQ:PRAH) have been given an average rating of “Buy” by the fourteen research firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $92.50.
Several equities research analysts have weighed in on the company. Credit Suisse Group reaffirmed an “outperform” rating and set a $104.00 price target (up from $101.00) on shares of PRA Health Sciences in a research report on Thursday. KeyCorp reaffirmed a “buy” rating and set a $100.00 price target on shares of PRA Health Sciences in a research report on Wednesday, January 31st. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “buy” rating and set a $101.00 price target on the stock in a research report on Wednesday, January 17th. Mizuho set a $87.00 price target on PRA Health Sciences and gave the stock a “buy” rating in a research report on Friday, December 1st. Finally, BidaskClub downgraded PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 5th.
In other news, VP Linda Baddour sold 67,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $90.27, for a total transaction of $6,048,090.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP David W. Dockhorn sold 72,850 shares of the firm’s stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. Following the sale, the executive vice president now owns 72,850 shares in the company, valued at $6,616,965.50. The disclosure for this sale can be found here. Insiders have sold a total of 212,700 shares of company stock worth $19,282,021 over the last 90 days. Insiders own 2.10% of the company’s stock.
PRA Health Sciences (NASDAQ PRAH) traded up $3.19 during midday trading on Wednesday, hitting $86.18. The company had a trading volume of 652,800 shares, compared to its average volume of 444,659. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.90 and a current ratio of 0.90. PRA Health Sciences has a 52-week low of $57.72 and a 52-week high of $95.90. The firm has a market cap of $5,497.50, a P/E ratio of 63.54, a price-to-earnings-growth ratio of 1.16 and a beta of 0.32.
PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, February 21st. The medical research company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.02. The firm had revenue of $568.80 million for the quarter, compared to the consensus estimate of $543.78 million. PRA Health Sciences had a return on equity of 22.77% and a net margin of 3.85%. The firm’s revenue was up 37.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.71 EPS. sell-side analysts predict that PRA Health Sciences will post 3.99 earnings per share for the current year.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.